Cannabidiol (CBD) Found to Reduce Seizure Frequency in Phase III Trial
The oral administration of CBD (cannabidiol) reduces seizure frequency in children with intractable epilepsy, according to placebo-controlled, randomized trial data published in The New England Journal of Medicine. In this double-blind, placebo-controlled trial, they randomly assigned 120 children and young adults with the Dravet syndrome and drug-resistant seizures to receive either cannabidiol oral solution at a dose of 20 mg per kilogram of body weight per day or placebo, in addition to standard antiepileptic treatment. The primary end point was the change in convulsive-seizure frequency over a 14-week treatment period, as compared with a 4-week baseline period.
A team of investigators from the United States and England evaluated the effects of pharmaceutically standardized cannabidiol extracts (aka Epidiolex) versus placebo in 120 children and young adults with treatment-resistant Dravet syndrome.
“The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 to 14.1 with placebo.”
Among patients with the Dravet syndrome, cannabidiol resulted in a greater reduction in convulsive-seizure frequency than placebo.